Clinical trials
Completed Arterial Occlusive Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| C. R. Bard | 3 |
| ARCA Biopharma, Inc. | 2 |
| AnGes USA, Inc. | 2 |
| Brigham and Women's Hospital | 2 |
| Duke University | 2 |
| Johns Hopkins University | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Siemens Healthineers Endovascular Robotics, Inc. | 2 |
| W.L.Gore & Associates | 2 |
| Abbott Medical Devices | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arterial Occlusive Diseases | 47 |
| Cardiovascular Diseases | 19 |
| Coronary Artery Disease | 16 |
| Vascular Diseases | 16 |
| Peripheral Arterial Disease | 15 |
| Peripheral Vascular Diseases | 15 |
| Coronary Disease | 14 |
| Arteriosclerosis | 13 |
| Myocardial Ischemia | 11 |
| Atherosclerosis | 10 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.